78 citations
,
March 2017 in “JAMA Dermatology” Tofacitinib helped regrow hair in people with severe alopecia, but side effects occurred and benefits stopped after treatment ended.
66 citations
,
December 2018 in “Dermatology” Both ruxolitinib and tofacitinib are effective and safe for treating severe alopecia areata, but relapses are common.
40 citations
,
September 2018 in “Journal of the American Academy of Dermatology” Tofacitinib helped some young children with severe hair loss grow their hair back without bad side effects.
39 citations
,
January 2019 in “Journal of the American Academy of Dermatology” Tofacitinib may help treat severe childhood alopecia areata, but risks require careful consideration.
30 citations
,
May 2016 in “Expert Opinion on Biological Therapy” New treatments targeting immune pathways show promise for severe hair loss but need more research for safety and effectiveness.
23 citations
,
September 2019 in “Journal of The American Academy of Dermatology” Tofacitinib and oral minoxidil together effectively regrow hair in severe alopecia areata patients.
20 citations
,
January 2012 in “International journal of trichology” Steroids are the best treatment for Alopecia Areata with few side effects.
17 citations
,
March 2018 in “Pediatric dermatology” Hydroxychloroquine may help treat alopecia areata in children.
14 citations
,
January 2017 in “Annals of Dermatology” Low-dose methotrexate effectively regrows hair in many alopecia areata patients but can cause some side effects.
12 citations
,
August 2019 in “Dermatitis” Dupilumab for skin problems might reactivate hair loss in some patients.
11 citations
,
February 2021 in “Journal of Cosmetic Dermatology” Oral tofacitinib helped regrow hair in over half of the patients with severe alopecia, but relapses and side effects were common.
11 citations
,
January 2018 in “Acta dermato-venereologica” Tofacitinib works better and is more tolerable for severe alopecia than conventional treatments and DPCP immunotherapy.
10 citations
,
January 2013 in “Faṣlnāmah-i bīmārīhā-yi pūst” Vitamin D levels are not linked to alopecia areata.
9 citations
,
October 2019 in “Dermatologic Therapy” Oral tofacitinib has a moderate success rate and is generally safe for treating hair loss in some patients.
5 citations
,
January 2020 in “Acta dermatovenerologica Alpina, Pannonica et Adriatica (Tiskana izd.)” Injecting platelet-rich plasma or applying it with a laser or microneedling can treat hair loss effectively. The laser and microneedling methods cause less pain.
4 citations
,
October 2024 in “American Journal of Clinical Dermatology” Ritlecitinib improved hair regrowth and emotional well-being in some alopecia areata patients.
3 citations
,
March 2020 in “International Journal of Dermatology” Tildrakizumab showed limited effectiveness in treating chronic alopecia areata in a small group of patients.
2 citations
,
April 2025 in “Dermatology and Therapy” Alopecia areata affects quality of life more in adolescents than adults.
2 citations
,
April 2024 in “Dermatology Practical & Conceptual” Tofacitinib and baricitinib are effective and safe for treating severe alopecia areata, especially in younger people.
2 citations
,
January 2023 in “Dermatology Practical & Conceptual” AB+ blood group is more common in alopecia areata patients.
2 citations
,
April 2019 in “Dermatologic Therapy” A patient with alopecia had hair regrowth with tofacitinib but developed a skin reaction, choosing to continue the treatment despite the side effect.
1 citations
,
January 2024 in “Annals of Dermatology” Examining hair shape can help predict Alopecia Areata's progression.
1 citations
,
January 2022 in “Medical Science” People with Alopecia Areata have a higher risk of heart-related health issues.
1 citations
,
December 2020 in “Dermatology Archives” Systemic steroids temporarily improve severe alopecia areata in children but often lead to relapse.
1 citations
,
August 2019 in “Australasian journal of dermatology” Immunotherapy can help treat severe alopecia areata.
March 2026 in “Journal of Pakistan Association of Dermatologists” Tofacitinib helps hair regrowth in alopecia areata but relapse is common after stopping treatment.
March 2026 in “American Journal of Clinical Dermatology” Ritlecitinib is effective and safe for long-term use in treating severe alopecia areata in people aged 12 and older.
March 2026 in “Dermatology and Therapy” Distinct miRNA signatures could help diagnose and treat severe Alopecia Areata.
November 2025 in “SKIN The Journal of Cutaneous Medicine” Upadacitinib effectively treats severe alopecia areata and is safe.
November 2025 in “Clinical Cosmetic and Investigational Dermatology” Tofacitinib is effective and safe for treating severe alopecia areata.